A number of immunoinflammatory and profibrotic mechanisms are recognized in the pathogenesis of broad sclerotic skin processes and, more specifically, morphoea. However, the precise aetiopathogenesis is complex and remains unclear. Morphoea is clinically heterogeneous, with variable anatomical patterning, depth of tissue involvement and sclerotic, inflammatory, atrophic and dyspigmented morphology. Underlying mechanisms determining these reproducible clinical subsets are poorly understood but of great clinical and therapeutic relevance. Regional susceptibility mechanisms (e.g. environmental triggers, mosaicism and positional identity) together with distinct pathogenic determinants (including innate, adaptive and imbalanced pro-and antifibrotic signalling pathways) are likely implicated. In the age of genetic profiling and personalized medicine, improved characterization of the environmental, systemic, local, genetic and immunopathological factors underpinning morphoea pathogenesis may open the door to novel targeted therapeutic approaches.
What's already known about this topic?
• Morphoea has a number of distinct clinical subsets with variable anatomical distribution, morphology and depth of tissue involvement.
• Susceptibility mechanisms (including genetics and underlying autoimmunity) and environmental triggers are at play in the pathogenesis of morphoea.
• A variety of innate and adaptive inflammatory and profibrotic immunopathogenic mechanisms and signalling pathways have demonstrated roles in the pathogenesis of sclerotic skin disease What does this study add?
• We expand on current limited understanding of morphoea pathogenesis.
• We propose the key inciting role of epidermal keratinocytes in morphoea pathogenesis based on the Blaschkoid nature of linear morphoea, and recognized role of keratinocyte-derived factors and epidermal-dermal signalling pathways in the pathogenesis of sclerotic skin disease.
• We review underlying genetic and immunopathological mechanisms in morphoea and how these link to clinical subsets.
• We present possible future therapeutic approaches in sclerotic skin disease and morphoea.
A review of morphoea pathogenesis is timely, with improved understanding of underlying molecular mechanisms likely to bring about the advent of more targeted therapeutic approaches. However, the clinical heterogeneity of morphoea, with variable anatomical patterning, morphology and depth of tissue involvement observed both within and between individuals, poses many clinical and pathogenic challenges (see Fig. 1 ). While key aetiological, immunoinflammatory and profibrotic molecular mechanisms are likely shared across these subsets of morphoea, there must be underlying determinants of clinical heterogeneity. Unmasking the genetic and molecular basis of this reproducibly observed clinical variability in morphoea has great therapeutic potential.
Susceptibility mechanisms
Systemic and regional genetic and epigenetic susceptibility mechanisms are all potentially at play in morphoea (see Figs 1 and 2 ). Certain human leucocyte antigen (HLA) subtypes, including HLA-DRB1*04:04 and HLA-B*37, infer increased susceptibility, especially in generalized and linear subtypes, 1 and morphoea is reported in first-or second-degree relatives in 2% of cases. [2] [3] [4] A personal or family history of autoimmune or rheumatological diseases is seen in up to 46% of those with morphoea, 2,5-9 sometimes more frequently in generalized or linear subtypes. 2, 7 Hence, one may speculate that a shared susceptibility locus exists for these disorders. As such, the systemic autoimmune nature of morphoea is further recognized by a variety of autoantibodies; 2, 7, 10, 11 antinuclear antibodies (ANA) can occur in 18-68%. 2, 9, [12] [13] [14] [15] [16] [17] [18] [19] [20] Notably, more of those with ANA positivity appear to have extracutaneous manifestations.
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Distinct genetic 'intrinsic subsets' in systemic sclerosis (SSc) have been described, with reproducible and temporally stable gene expression profiles correlating to inflammatory and fibroproliferative signatures, and related clinical heterogeneity. [21] [22] [23] [24] [25] Significantly, differences in gene expression can be mapped not only to fibroblasts, but also to epithelial, endothelial, smooth muscle, and T and B cells. 24, 26 Genome-wide expression profiling of skin biopsies from three patients with morphoea linked them to the inflammatory signature, 23 hence implicating mediators such as interferon (IFN), interleukin (IL)-13, chemokine (C-C motif) ligand (CCL)2, early growth response-1 gene and others in pathogenesis. [21] [22] [23] [24] [25] Indeed, IFN-
Linking clinical morphoea variability (anatomical, morphology and depth of tissue involvement) to possible underlying genetic and molecular mechanisms. Specifically, anatomical distributions may be explained by certain factors of regional diversification, while variations in morphology and depth of tissue involvement may be determined by differing immunoinflammatory and pro-/antifibrotic pathways. Wnt, Wingless and int homologue; Fli, friend leukaemia integrated transcription factor; TGF, transforming growth factor; FGF, fibroblast growth factor; IFN, interferon; TLR, Toll-like receptor; STAT, signal transducer and activator of transcription; NF-jB, nuclear factor kappa B; IL, interleukin; TNF, tumour necrosis factor; CCL2, chemokine (C-C motif) ligand 2; CTGF, connective tissue growth factor; MMP, matrix metallopeptidase; TIMP, tissue inhibitor of metalloproteinase; Shh, Sonic hedgehog; MSH, melanocyte-stimulating hormone.
c-inducible protein 10 (IP10, CXCL10) is elevated in children with morphoea and acts via CXC-chemokine-receptor 3 to attract inflammatory cells to the skin. 27 Of great potential relevance to regional genetic susceptibility is evidence that linear morphoea follows Blaschko's lines of epidermal development, suggesting likely mosaicism for a mutation that causes increased susceptibility to morphoea at certain sites (see Figs 1 and 2) . [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] However, that a fibroblast-driven dermal process can be Blaschkoid raises many unanswered questions, but its feasibility is perhaps substantiated by the existence of other similar conditions, including focal dermal hypoplasia (FDH; Goltz syndrome) 40 and a recent report of Blaschkoid granuloma annulare. 41 This may highlight the potential role of epidermally derived signalling and immunoinflammatory pathways in the pathogenesis of morphoea. Finally, epigenetic mechanisms may provide a potential link between genetic susceptibility, environmental aetiology and site specificity (see Fig. 1 ). Altered patterns of histone acetylation and DNA methylation at multiple genetic loci have been demonstrated in SSc. This has included transcriptional silencing of repressive genes in SSc fibroblasts, resulting in increased profibrotic gene expression and transforming growth factor (TGF)-b-induced responses. 42, 43 The importance of microRNAs (miRNAs) in the pathogenesis of skin fibrosis is also emerging. Twenty-six miRNAs are shown to be deregulated in SSc skin and isolated fibroblasts, some forming part of a positive feedback profibrotic mechanism activated by TGF-b. 44 miR-21 and miR-155 are profibrotic and show elevated expression in SSc skin. 45 These miRNAs are, in turn, regulated by TGF-b and hence have, as their predicted targets, genes involved in matrix repair and remodelling, such as collagens, matrix metallopeptidases (MMPs) and integrins. 46 Conversely, miR-30b levels are inversely correlated to modified Rodnan skin scores (mRSS) and appear to be related to increased platelet-derived growth factor (PDGF) expression on dermal fibroblasts. 47 Notably, downregulation of antifibrotic miR-7 and miR-196a50 have been demonstrated in the skin and serum of patients with morphoea, [48] [49] [50] potentially contributing to overproduction of collagen type I.
Triggering events
An array of environmental triggers is widely reported in the aetiology of morphoea, seemingly linking susceptibility mechanisms and eventual, but not inevitable, disease onset (see Figs 1 and 2 ). [51] [52] [53] Trauma, in the form of insect bites, injection/vaccination, repeated friction, surgery, penetrating trauma, radiotherapy and extreme exercise, may trigger morphoea in up to 16% of adults and 9% of children. 5, 54 Traumarelated morphoea may occur at the affected site, or a more systemic response may be triggered, with site-unrelated skin sclerosis also seen. Of relevance is isomorphic disseminated plaque morphoea, which occurs symmetrically and at sites of repeated minor friction-induced trauma along the waistline, bra straps and inguinal creases (see Fig. 1 ). 54, 55 The mechanisms of trauma-related morphoea remain somewhat elusive; enhanced innate signalling via Toll-like receptor (TLR) ligands inducing fibroblast activation and an abnormal wound-healing response has been proposed. 56 Several vaccinations are implicated temporally and anatomically with morphoea, including hepatitis B, tetanus, vitamin B12 and more. [57] [58] [59] [60] [61] [62] [63] [64] Whether this is purely trauma related (due to vessel injury, tissue hypoxia and subsequent immune activation) or potentially due to common adjuvant vaccine constituents, remains uncertain. 65 Somewhat similarly, postirradiation morphoea predominantly occurs at the site of radiation and within 12 months of completing treatment (most commonly in the setting of breast cancer). 66, 67 However, up to one-quarter of cases may extend beyond the radiation field and the immunopathology of this is not clear, 66, 67 but increased IL-4, IL-5 and TGF-b is suggested. 68 Infection also triggers morphoea, 5 and, perhaps most controversially, Borrelia species are associated with morphoea in some studies. 51, [69] [70] [71] [72] [73] [74] Finally, various drugs can seemingly initiate the development of skin sclerosis, [75] [76] [77] [78] [79] and drug cessation does not necessarily result in resolution. 78, 80 Specific drugrelated lymphocyte responses and autoantibody production, with consequent vascular damage, reactive oxygen species, IL-1, tumour necrosis factor (TNF)-a and TGF-b production may be involved.
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Pathogenesis
A plausible model of morphoea pathogenesis would involve a triggering event in a susceptible individual that results in a cascade of innate and adaptive immunoinflammatory and profibrotic responses, involving potential epidermal signalling and mesenchymal drivers (see Fig. 2 ). Notwithstanding morphological variation and distinct patterning observed in different morphoea subsets, many of these fundamental immunopathogenic mechanisms are likely to be shared.
The epidermis
Keratinocytes
A number of factors known to be involved in dermal fibrosis can be produced by keratinocytes, including TGF-b, IL-1, IL-6, TNF-a, PDGF, fibroblast growth factor (FGF), CCL2, endothelin (ET)-1, fibrillin-1, friend leukaemia integrated transcription factor (Fli)-1, S100A9, a-melanocyte-stimulating hormone (a-MSH) and others (see Fig. 2 ). 82 FGF receptors 1 and 2 are also linked to S100A9 activity and fibrosis. FGF receptor knockout mice demonstrate loss of claudins and occludin, which causes transepidermal water loss, severe xerosis and resultant activation of cd T cells and keratinocytes to produce IL-1, S100A8 and S100A9, promoting a profibrotic response. 89 a-MSH mediates melanocyte pigment production via melanocortin-1 receptors (MC1R), is upregulated in the epidermis and fibroblasts of human burn wounds and hypertrophic scars, 92 and modulates pro-and anti-inflammatory cytokines produced by keratinocytes, monocytes and fibroblasts. 93 Conversely, and signifying its physiological homeostatic role, a-MSH (via MC1R) antagonizes cutaneous fibrosis induced by repeated TGF-b exposure and bleomycin. [94] [95] [96] As such, MC1R knockout mice have demonstrated a susceptibility to fibrosis. 97 Fibrillin-1 is a major component of the microfibrillar ECM network. Its expression has been associated with diffuse cutaneous SSc of the 'fibroproliferative' signature, 23 and antibodies against fibrillin-1 have been documented in patients with morphoea and SSc. 98 Stiff skin syndrome is due to mutations in the domain of fibrillin-1 that mediates integrin binding, and is characterized by sclerotic skin, usually over the entire body, somewhat reminiscent of pansclerotic morphoea.
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Further evidence connecting fibrillin-1 to sclerotic skin disease is the suggested link between variation at the fibrillin-1 gene locus and SSc in Choctaw Indians. 101 Finally, keratinocyte-derived transcription factor Fli-1 has a demonstrated role in dermal fibrosis mouse models and SSc. Downregulation of Fli-1 induces a SSc-like phenotype in fibroblasts, vascular endothelium and macrophages. Additionally, keratinocyte Fli-1 knockout mice exhibit enhanced skin fibrosis with increased IL-1, IL-6 and IL-8 expression. 102 
Epidermal-dermal signalling and developmental pathways
Epidermal-dermal morphogenic signalling pathways [including Wingless and int homologue (Wnt), Sonic hedgehog (Shh) and Jagged-Notch] involved in embryonic development, tissue patterning, morphogenesis and wound repair, are of increasing interest in skin fibrosis (see Fig. 2) . 89, [103] [104] [105] [106] [107] These pathways have been implicated in SSc and are also of potential relevance to patterning and morphological variation seen clinically in morphoea, [108] [109] [110] [111] [112] although little is confirmed in the present literature in this regard. Jagged-Notch pathways, which control formation of boundaries between groups of cells during embryogenesis and mediate epithelial-mesenchymal transition, are overactivated in fibroblasts in SSc. 46, 113 Similarly, Shh is elevated in fibroblasts, endothelial cells and keratinocytes of patients with SSc, allowing degradation of Gli proteins, thus promoting fibrosis. 46, 110, 114 Finally, and perhaps especially significant, is Wnt signalling, which originates in the epidermis. Normal stimulation of fibroblasts with Wnt ligands results in b-catenin-mediated expression of collagen, other matrix proteins, CTGF, enhanced fibroblast proliferation, myofibroblast differentiation and increased cell migration. [115] [116] [117] [118] [119] Genome expression profiling has demonstrated elevated expression of several Wnt ligands, receptors and decreased expression of Wnt antagonists in SSc. 114, 115, [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] Of further relevance to skin sclerosis, Wntb-catenin signalling and TGF-b pathways are known to interact, and peroxisome proliferator-activated receptor (PPAR)-c (a recognized antifibrotic receptor that inhibits Wnt-b-catenin signalling) is decreased in SSc, thus promoting fibrosis. 119 Additionally, Wnt signalling inhibits epidermal responsiveness to FGF receptors, providing another link between potentially important epidermal inciting pathways and dermal fibrosis. Finally, b-catenin-independent keratinocyte-derived Wnt5a is highly expressed in SSc fibroblasts, and Wnt5a knockout mice appear resistant to bleomycin-induced skin sclerosis. 127 
Immunoinflammation
Innate responses
The potential role of the innate immune system in triggering the complex profibrotic cascade is of increasing interest. Type 1 IFNs are key innate mediators and are intimately linked with TLR signalling (see Fig. 2 ). TLR-3 is involved in downstream increases in inflammatory and profibrotic cytokines and chemokines such as IL-6 and IP10 (CXCL10), as well as increased responsiveness of fibroblasts to TGF-b. 46 Additionally, synthetic TLR3 ligand induces the expression of several ECM genes in fibroblasts and dermal fibrosis in mouse models.
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IFN-regulatory factor 5 (IRF5) is a transcription factor involved in TLR signalling and activation of target IFN genes.
129 IRF5 has been coined a susceptibility factor to SSc and its potential role in pulmonary fibrosis has been identified. 129 Further implicating IFN in fibrosis is signal transducer and activator of transcription 4 (STAT4), which induces expression of type 1 IFNs, and STAT4-null mice exposed to bleomycin develop reduced fibrosis compared with controls.
129 STAT4 is also pivotal in proinflammatory cytokine production, including TNF-a, IL-2 and IL-6; hence, its role in an inflammatory model of fibrosis is potentially relevant to morphoea, where an inflammatory signature has been demonstrated in some. 23 Nuclear factor kappa B, the master regulator of innate immune signalling, is important in skin homeostasis and more recently a profibrotic role of the c-Rel subunit expression within keratinocytes has been suggested, with abnormal epidermal expression patterns in SSc skin compared with healthy controls. 130 Inflammasome activation and IL-1b production is also implicated in many animal models of fibrosis, and has a potential role in SSc (see Figs 1 and 2) . 131, 132 Indeed, NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome and IL-1b levels correlate with mRSS and immunohistochemistry staining shows strong NLRP3 and IL1b staining in the epidermis of SSc skin. 132 Similarly, ET-1 levels correlate with NLRP3 and mRSS, ET-1 receptors are increased in SSc, [131] [132] [133] [134] [135] [136] and external stimuli can induce ET-1 and concurrent TGF-b production by oral mucosal keratinocytes in oral submucous fibrosis. 133 
Adaptive responses
A cytokine profile-based conceptual model of the immunopathology of morphoea was recently proposed, 137 and has been supported by further cytokine expression profiling. [138] [139] [140] [141] [142] An early active disease phase characterized by inflammation with a T-helper (Th)1 cytokine response (mediated by IL-2, TNF-a and IL-6) appears to be followed by ongoing inflammation and initiation of fibrosis driven by Th17-related IL-1, IL-17, IL-22 and TGF-b production. Subsequent progression to a final fibrotic and atrophic phase then occurs, predominated by Th2 cytokines (IL-4 and IL-13) (see Figs 1 and 2 ). 137 Correspondingly, raised IL-2, IL-2 receptor and TNF-a levels are seen in early-phase morphoea, 15, 138, 143 and correlate with IL-4 and IL-6 levels, objective skin scores, [137] [138] [139] antihistone and anti-single-stranded DNA antibodies. 141 Serum IL-1 and IL-6 levels (Th17 inducers) are also elevated during early disease (< 24 months), while levels of Th17 effectors (IL-17F and IL-22) become elevated later (24-48 months). 137, 144 IL-6, stimulated by IL-1, is required for wound healing and fibroblast activity, and is intimately involved in morphoea. 145 In response to injury, IL-1, via IL-6 and PDGF, promotes fibroblast proliferation, resultant transcription of type I, III and IV collagens, 82, 146 and CTGF expression. 147 IL-1 pathways can also activate fibroblasts in SSc. 148 Further, low IL-17C with high IL-17E and IL-22 increases fibroblast profibrotic responses, which is further enhanced in the presence of IL-22-and TNF-activated keratinocytes in both SSc and morphoea. 149 IL-17A also appears important, with levels decreasing in correlation with TGF-b and IL-22 in the setting of polymerized collagen treatment and associated normalization of dermal architecture in morphoea skin. 150 TGF-b is recognized as a potential master regulator of wound healing and a driver of pathological fibrosis. 134 Increased levels of TGF-b and TGF-b receptor I and II have been demonstrated in skin biopsies and sera of patients with morphoea and SSc. 137, [151] [152] [153] [154] [155] [156] In addition, and perhaps highly relevant, is the key role of TGF-b in regulating normal embryonic and fetal growth and development, as well as postnatal growth of connective tissue. A number of MMPs and tissue inhibitor of metalloproteinases are also deregulated by TGF-b expression, 157 promoting ECM production and limiting degradation. MMP-12 is overexpressed in SSc and associated with the extent of skin disease, disease duration and severity of pulmonary fibrosis. 158, 159 Similarly, MMP-12 may be implicated in the antifibrotic effects of ultraviolet A1 phototherapy. 160 Finally in this cytokine profile-based model of morphoea, Th2-related IL-4 and IL-13 appear to be linked to the late fibrotic, as well as final atrophic and/or hyperpigmented, phases of morphoea morphology. Regarding fibrosis, IL-4 and IL-13 upregulate collagen synthesis, inhibit collagenase activity, 142 with elevated IL-13 levels have been demonstrated in some patients with morphoea in the late fibrotic stage. 139 In addition, IL-13 pathways may be interlinked with TGF-b and CCL2, and recent gene expression profiling of patients with morphoea confirmed increased IL-13 and CCL2 activity. 23 The role of B cells in morphoea is also well supported. As mentioned, a personal or family history of an associated autoimmune or rheumatological diagnosis can occur in 9-46% of those with morphoea. 2, 5, [7] [8] [9] Accordingly, the systemic autoimmune nature of morphoea is further recognized by a variety of autoantibodies, 2, 7, 10, 11 and an increased level of B-cell activating factor in the serum of affected patients further infers systemic autoimmunity. 161 ANA can occur in 18-68% of cases. 2, 9, [12] [13] [14] [15] [16] [17] [18] [19] [20] Furthermore, B cells are known to produce profibrotic cytokines, such as IL-6 and TGF-b, promote a profibrotic Th2 response and regulatory B cells (which inhibit Th1 and Th17) are decreased in SSc.
Mesenchyme and fibroblasts
Myofibroblasts are the key effecter cell in fibrosis. Upon injury, fibroblasts migrate towards a wound and, under the influence of growth factors, differentiate into secretory myofibroblasts, which are central to repair during wound healing. 114 In wounds, the process of myofibroblast activation and population expansion are appropriately switched off via apoptosis or deactivation. In contrast, this physiological balance is deregulated in pathological fibrosis, including morphoea, and a profibrotic environment rich in activating signals such as TGF-b, FGFs and CTGF inappropriately persists (see Figs 1 and 2). 114 Studies support the role of fibroblast transdifferentiation in fibrotic skin disease, which expands resident fibroblast populations from many other differentiated cell lineages. Bone morphogenetic protein 2 (BMP-2)-induced TNF-a, TGF-b Smad signalling, and CTGF, FGF as well as developmental pathways (Wnt, Shh and Jagged-Notch), all potentially induce epithelial to myofibroblast transformation in keratinocytes, and are separately implicated in skin fibrosis. [162] [163] [164] [165] [166] [167] Interestingly, and of potential relevance to Blaschkoid morphoea, is the increased keratinocyte expression of a-smooth muscle actin in patients with stiff skin syndrome (fibrillin-1 gene mutation) and the related lack of normal basal-layer keratinocyte columnar organization. 99, 100 In addition to transdifferentiation, the aberrant differentiation of circulating bone marrow-derived mesenchymal progenitors (fibrocytes) into fibroblasts and myofibroblasts is also described in SSc.
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Mesenchymal patterning and location-specific gene expression
Fibroblasts show location-specific gene expression, formally referred to as 'positional identity'. The master regulating genes of positional identity during development are the homeodomain genes of the HOX subfamily, along with their co-factors, TALE. HOX genes encode transcriptional factors that determine the positional identity of fibroblasts along anterior-posterior and secondary axes. 108, [170] [171] [172] [173] Hence, fibroblasts from different sources, although immunophenotypically very similar, display distinct and site-specific HOX and TALE signatures; for example, HOXA13 is expressed in distal fibroblasts and is required for normal toe, finger and foreskin development. 170, 171 Importantly, site-specific HOX and TALE transcriptional patterns remain stable throughout life and hence epigenetic factors are at play. 170, 171 As one may elucidate, such site-specific gene signatures are not only responsible for determining position and patterning during development, but also play a pivotal role in subsequent downstream orchestration of site-specific mesenchymal cell differentiation and related pathway signalling, acting as micromanagers of adult cell differentiation. 108, 174 Many patterning and developmental pathways, including Shh and Wnt, are involved, 175 and the resultant regional diversification, which can be traced back to specific axial positions, may suggest that fibroblasts at different sites should actually be considered as groups of distinctly differentiated cells. 108, [175] [176] [177] [178] Importantly, these many pathways, which are instrumental in developmental patterning, positional identity, regional-specific mesenchymal differentiation and overlying epidermal fate, are intricately linked to pathogenesis of fibrosis via site-specific expression of factors, including TGF-b, Wnt, FGFs, BMP, receptor kinase, phosphatase families and G protein signalling (see Fig. 1 ). 108, 171 Hence, somewhat unsurprisingly, their pathogenic role in SSc-specific skin and internal organ disease is documented, 46, 179 and although likely of relevance, currently there are no specific investigations into the role of these mechanisms in morphoea (see Fig. 2 ).
Potential molecular mechanism of morphoea clinical subsets
Although there are clearly several shared aetiopathogenic mechanisms across the spectrum of morphoea, there must be underlying determinants of anatomical patterning and the variably sclerotic, atrophic and pigmented morphology observed clinically (see Fig. 1 ). In some, this will likely reflect local susceptibility factors, including regional genetic and/or epigenetic perturbation, as described above. While in others it may suggest distinct pathogenic mechanisms. As alluded to, morphoea classically evolves through three clinical stages: active inflammation, followed by sclerosis and then dyspigmentation and/ or atrophy. However, there is marked variation within this phenotypic spectrum, both between and within individual patients; for example, atrophoderma may present without clinically apparent preceding inflammation or sclerosis in some or all lesions. Epigenetics, perturbation of homeostatic signalling (e.g. 
Implications for therapy
With improved understanding of the molecular pathogenesis of morphoea, it is likely that more precisely targeted biological therapies directed towards specific immunoinflammatory and connective tissue repair pathways will become increasingly available (see Table 1 ). As discussed, the role of activated T cells is described in the pathogenesis of morphoea and well understood in SSc and animal models of skin fibrosis. 137, 180, 181 Abatacept (recombinant IgG1 fusion protein to cytotoxic T-lymphocyte antigen 4), inhibits activated T cells by binding to CD80 and CD86, thereby blocking interactions with CD28. Thus, abatacept has resulted in significant improvement in two cases of deep and extensive morphoea and further cases of SSc. [182] [183] [184] Infliximab (chimeric monoclonal antibody to TNF-a) has induced remission in one case of generalized morphoea and three cases of eosinophilic fasciitis. [185] [186] [187] [188] As a Th1 cytokine linked to the early inflammatory phase of morphoea, one can elucidate how TNF-a inhibition could be a useful therapy. However, etanercept (TNF-a receptor fusion protein) has been linked to the subsequent development of disseminated plaque morphoea (at sites related and completely separate to injections) in a patient with psoriasis receiving therapy for 18 months. 189 Whether this was due to injection site-related trauma and a subsequent systemic response, or a trauma-unrelated paradoxical immunological drug response, remains unclear. Imatinib (tyrosine kinase inhibitor) via anti-TGF-b and PDGF effects, showed promising results in three cases of morphoea (see Table 1 ). [190] [191] [192] Tocilizumab (humanized IL-6 receptor monoclonal antibody) has been used with some success in SSc and in 5 paediatric cases of severe treatment resistant morphoea. [193] [194] [195] In experimental SSc mouse models, PPAR (c and a) agonist IVA337 can decrease ECM deposition and TGF-b related Smad signalling. 196 And, finally, PDE4 inhibition (Apremalast â ) reduces and inhibits fibrosis in a mouse model of sclerotic skin disease, with amelioration of skin fibrosis in sclerodermoid graft-versus-host disease. 102 Based on present understanding of pathogenesis, future targets for morphoea could include IL-1, IL-13, IL-17E, TGF-b or Wnt signalling pathway mediators, among others (see Table 1 ). Importantly, the potential for nonsystemic routes of administration, such as topical preparations in optimized vehicles, long-acting patches, or local intradermal or subcutaneous injection, may improve tolerability and increase therapeutic benefit-to-risk ratios.
Conclusions
The complexity of morphoea aetiopathogenesis is clear. While some broadly involved immunoinflammatory and profibrotic signalling cascades are elucidated, an overlay of clinical heterogeneity means regional susceptibility mechanisms and distinct pathogenic determinants are likely implicated. In the age of genetic profiling and advanced molecular science, more precise characterization of systemic and local genetic and immunopathological factors underpinning the anatomical and morphological variability in morphoea, may open the door to novel targeted therapeutic approaches.
